GPM6B Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population in which the GPM6B gene has been disrupted to create a loss-of-function model in a human T lymphocyte background. This polyclonal knockout product is generated from the widely used Jurkat E6-1 immortalized cell line, providing a mixed population of edited cells that harbor heterogeneous mutations at the target locus. The absence of clonal selection preserves biological diversity within the knockout pool, making it suitable for studies where population-level responses rather than clonal artifacts are critical.
The host Jurkat cell line is a well-established model derived from the peripheral blood of a 14-year-old male with acute T cell leukemia. Jurkat T cells are extensively employed to investigate T cell receptor (TCR)-mediated signaling, apoptosis, cytokine production, and the molecular mechanisms of HIV infection. Their robust, reproducible activation responses to TCR stimulation, phorbol esters, and other immune stimuli render them an ideal platform for dissecting T cell biology. The immortalized nature of Jurkat cells enables long-term genetic manipulation and consistent functional assays, facilitating rigorous comparative analyses between wild-type and gene-disrupted states.
GPM6B encodes a neuronal membrane glycoprotein implicated in neurite outgrowth, cell adhesion, membrane trafficking, and cytoskeleton organization, yet its role in T lymphocytes is increasingly recognized. In Jurkat cells, GPM6B is positioned within the TCR signaling network, where it functions downstream of NFAT and SP1 transcription factors and upstream of Rac1 activation and ERK1/2 phosphorylation. It interacts with actin cytoskeleton proteins, membrane raft components, integrin ??1, and tetraspanin CD81 to coordinate actin polymerization and immunological synapse assembly. Key pathway effectors include TCR, LAT, PLC??1, Rac1, PAK, LIMK, and cofilin, linking receptor ligation to dynamic actin remodeling. GPM6B disruption impairs TCR-driven actin reorganization, attenuating the activation of MAPK and NF-??B cascades and reducing IL-2 production.
This knockout model holds significant relevance for T cell biology research, particularly in exploring the interplay between membrane organization and signaling outputs. Loss of GPM6B in Jurkat cells compromises efficient immunological synapse formation and downstream transcriptional programs, providing a tool to dissect how actin dynamics modulate T cell activation thresholds. The model is pertinent to T cell acute lymphoblastic leukemia research, given GPM6B??s potential involvement in leukemogenesis, as well as to studies of neuroinflammatory conditions such as multiple sclerosis, where T cell migration and adhesion are central. By linking membrane protein function to cytoskeletal rearrangements, these cells enable investigation of a poorly understood node in immune cell regulation.
Applications of GPM6B Knockout Jurkat Polyclonal Cells are diverse and supported by a range of quantitative assays. Researchers can employ western blotting to monitor phospho-ERK and phospho-NF-??B levels, flow cytometry to assess CD69 upregulation as an early activation marker, and IL-2 ELISA to quantify cytokine secretion. Luciferase reporter systems driven by NFAT/AP-1 response elements provide a versatile readout for TCR signaling strength, while immunofluorescence imaging of F-actin and synapse markers reveals structural defects in the immunological synapse. Complementary functional analyses include cell adhesion and migration assays, co-immunoprecipitation of GPM6B-associated complexes, and RT-qPCR profiling of cytokine gene expression. These tools collectively enable high-resolution studies of actin-dependent signaling in immune contexts, drug screening for immune modulators, and HIV infectivity assays. For further information, please contact Ascent Research.
